Telecom sector dynamics shifted significantly as SpaceX enhanced its Starlink Mobile service, raising competitive concerns for established players. T-Mobile’s stock fell by 13%, while AT&T and Verizon also saw declines of 10% each. Conversely, cellular tower companies like Crown Castle, SBA Communications, and American Tower experienced gains, rising by 12%, 6%, and nearly 8%, respectively.
Teva Pharmaceutical Industries reported a 6% increase in its shares following FDA approval for Weltruza, a long-acting injectable treatment for schizophrenia in adults. In contrast, Avient, a chemical and plastics manufacturer, saw its stock drop over 7% after CEO Ashish Khandpur’s resignation, with Mike Frank stepping in as his successor.
Archer Aviation’s shares climbed by 3% after Barclays began coverage of the company, assigning an overweight rating and a price target of $8, indicating a potential 69% upside. However, Delta Air Lines experienced a nearly 2% decline as its third-quarter earnings fell short of expectations, attributing the downturn to increased fuel costs that prompted a revised full-year earnings outlook.
In other notable moves, Lumentum’s shares surged approximately 7% after CEO Michael Hurlston announced the company’s optical components are sold out through 2029, with projected difficulties in meeting demand. Managed care providers also reacted to the Centers for Medicare & Medicaid Services’ 2027 Star Ratings, with Humana’s shares rising 12% due to improved ratings, while Alignment Healthcare’s stock plummeted nearly 14%. Apple shares declined nearly 2% after reports of reduced component orders for its iPhone 18 Pro, reflecting weaker-than-expected demand. Park Aerospace reported a 9% drop in stock, despite earnings showing improvement year-on-year. Meanwhile, Freeport-McMoRan gained 3% as gold prices rose.
Why this story matters: Changes in telecom and healthcare sectors highlight shifting market dynamics and competition.
Key takeaway: Companies with strong product demand and positive regulatory news generally see stock price increases, while those facing leadership changes or lower demand may decline.
Opposing viewpoint: Some analysts may argue that the reactions of companies are overstated and do not reflect long-term market trends.
